ZEPP Fundamental Analysis - ZEPP HEALTH CORP-ADR

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ZEPP. ZEPP was compared to 125 industry peers in the Electronic Equipment, Instruments & Components industry. ZEPP has a bad profitability rating. Also its financial health evaluation is rather negative. ZEPP is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ZEPP has reported negative net income.
The reported net income has been mixed in the past 5 years: ZEPP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ZEPP reported negative operating cash flow in multiple years.

1.2 Ratios

ZEPP's Return On Assets of -14.18% is on the low side compared to the rest of the industry. ZEPP is outperformed by 66.40% of its industry peers.
With a Return On Equity value of -34.61%, ZEPP is not doing good in the industry: 72.00% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROIC	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 37.59%, ZEPP is doing good in the industry, outperforming 62.40% of the companies in the same industry.
ZEPP's Gross Margin has improved in the last couple of years.
ZEPP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	37.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZEPP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ZEPP has been reduced compared to 5 years ago.
ZEPP has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.64 indicates that ZEPP is not a great score, but indicates only limited risk for bankruptcy at the moment.
ZEPP's Altman-Z score of 2.64 is on the low side compared to the rest of the industry. ZEPP is outperformed by 64.80% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that ZEPP is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEPP (0.85) is worse than 85.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Altman-Z	2.64

ROIC/WACCN/A

WACC6.57%

2.3 Liquidity

A Current Ratio of 1.10 indicates that ZEPP should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.10, ZEPP is doing worse than 87.20% of the companies in the same industry.
ZEPP has a Quick Ratio of 1.10. This is a bad value and indicates that ZEPP is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEPP's Quick ratio of 0.77 is on the low side compared to the rest of the industry. ZEPP is outperformed by 87.20% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.1
Quick Ratio	0.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.53% over the past year.
The Revenue for ZEPP has decreased by -42.69% in the past year. This is quite bad
ZEPP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.53% yearly.

EPS 1Y (TTM)23.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.29%

Revenue 1Y (TTM)-42.69%

Revenue growth 3Y-27.67%

Revenue growth 5Y-8.53%

Sales Q2Q%-75.35%

3.2 Future

ZEPP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.28% yearly.
Based on estimates for the next years, ZEPP will show a decrease in Revenue. The Revenue will decrease by -4.24% on average per year.

EPS Next Y85.63%

EPS Next 2Y38.52%

EPS Next 3Y25.28%

EPS Next 5YN/A

Revenue Next Year-49.23%

Revenue Next 2Y-16.57%

Revenue Next 3Y-4.24%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ZEPP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZEPP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ZEPP's earnings are expected to grow with 25.28% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.52%

EPS Next 3Y25.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ZEPP!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (1/16/2026, 8:04:00 PM)

After market: 23.02 0 (0%)

23.02

+0.52 (+2.31%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupTechnology Hardware & Equipment

GICS IndustryElectronic Equipment, Instruments & Components

Earnings (Last)11-04 2025-11-04/bmo

Earnings (Next)03-24 2026-03-24/bmo

Inst Owners48.68%

Inst Owner Change0%

Ins Owners5.91%

Ins Owner ChangeN/A

Market Cap1.38B

Revenue(TTM)352.86M

Net Income(TTM)-77.87M

Analysts85

Price Target63.07 (173.98%)

Short Float %7.52%

Short Ratio2.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)2.66%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)3.74%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.9
P/FCF	N/A
P/OCF	N/A
P/B	6.14
P/tB	6.86
EV/EBITDA	N/A

EPS(TTM)-2.96

EYN/A

EPS(NY)-0.88

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS3.33

BVpS3.75

TBVpS3.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	37.59%
FCFM	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

F-ScoreN/A

Asset Turnover0.36

Health

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.1
Quick Ratio	0.77
Altman-Z	2.64

F-ScoreN/A

WACC6.57%

ROIC/WACCN/A

Cap/Depr(3y)22.81%

Cap/Depr(5y)96.65%

Cap/Sales(3y)0.51%

Cap/Sales(5y)0.74%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)23.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.29%

EPS Next Y85.63%

EPS Next 2Y38.52%

EPS Next 3Y25.28%

EPS Next 5YN/A

Revenue 1Y (TTM)-42.69%

Revenue growth 3Y-27.67%

Revenue growth 5Y-8.53%

Sales Q2Q%-75.35%

Revenue Next Year-49.23%

Revenue Next 2Y-16.57%

Revenue Next 3Y-4.24%

Revenue Next 5YN/A

EBIT growth 1Y-91.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year49.29%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-162.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-156.9%

OCF growth 3YN/A

OCF growth 5YN/A

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZEPP.

What is the valuation status for ZEPP stock?

ChartMill assigns a valuation rating of 1 / 10 to ZEPP HEALTH CORP-ADR (ZEPP). This can be considered as Overvalued.

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?

ZEPP HEALTH CORP-ADR (ZEPP) has a profitability rating of 2 / 10.

What is the expected EPS growth for ZEPP HEALTH CORP-ADR (ZEPP) stock?

The Earnings per Share (EPS) of ZEPP HEALTH CORP-ADR (ZEPP) is expected to grow by 85.63% in the next year.

ZEPP HEALTH CORP-ADR (ZEPP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

What is the valuation status for ZEPP stock?

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?

What is the expected EPS growth for ZEPP HEALTH CORP-ADR (ZEPP) stock?